Yuhan Corporation Signs Exclusive Domestic Sales and Joint Promotion Agreement for 'Gleevec' with Novartis Korea
[Asia Economy Reporter Kum Boryeong] Yuhan Corporation announced on the 19th that it has signed an exclusive domestic sales and joint promotion agreement for the chronic myeloid leukemia and gastrointestinal stromal tumor treatment drug 'Gleevec' with Korea Novartis.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The sales revenue of Gleevec sold by Korea Novartis in the domestic market last year was approximately 52 billion KRW, which corresponds to about 3.5% of Yuhan Corporation's consolidated sales revenue for the most recent fiscal year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
